艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复

图示∶2010年12月即将出版的《中国特色医疗金鉴》登载的刘君主任及其机构

慢性艾滋病早期中医药治疗保障生命论证 红津液饮料面世 或将能预防艾滋病 更多来源∶新浪商业登载 http://vic.sina.com.cn/news/27/2010/1231/26801.html TOM新闻登载 http://post-social.news.tom.com/s/63000AD83310.html 中国青年网 健康频道 http://news.youth.cn/jk/201012/t20101231_1447239.htm  环球时报-环球网 http://news.163.com/10/1231/15/6P8B7PTU00014JB6.html  环球网 http://china.huanqiu.com/hot/2010-12/1390550.html

Three highlights of the pharmaceutical industry in China M & A remarkable
Author: Source: China Pharmaceutical News Posted by: Yiyun Category: Industry News Date: 2011-03-13 Today / Total View: 86/86

In 2010, the Ministry of Health and other ministries jointly issued by the three "speed up the restructuring of the pharmaceutical industry guidance," clearly the direction of industry consolidation and rationalization of the organizational structure of the target. For the status of the Chinese pharmaceutical industry mergers and acquisitions and opportunities, the organization recently released "2010 China M & A opportunities for the pharmaceutical industry analysis topics" that: a portfolio of policy initiative, has become a big pharmaceutical industry to promote the integration of the historic opportunity. Pharmaceutical company mergers and acquisitions continue to climax, and "bigger and stronger" is the reorganization of the pharmaceutical industry mergers and acquisitions in the next period of time of persistent theme.



Biopharmaceutical favored



Biotechnology is one of the fastest growing high-tech. The emerging bio-technology has been widely used in medical, agricultural, biological processing, resource development and utilization, and development of pharmaceutical and other industries had a profound impact. Biopharmaceutical industry is the use of modern biotechnology (including genetic engineering, cell engineering, enzyme engineering, microbial engineering, biochemical engineering and protein engineering) production of bio-pharmaceutical industry, which is characterized by high profitability and high growth. Biomedical industry in China in 2009 the scale of 850 billion yuan, up 24.6%. As more and more into the health insurance directory of biological drugs, and drug development to accelerate the pace of innovation, the future can be expected to keep rising industrial output value of the biopharmaceutical industry.



Currently, national efforts to grow through increased investment in the bio-pharmaceutical industry research and development and innovation, thus promoting the bio-industry. In the "second Five-Year" plan, China will further promote the proprietary biotechnology industry, and promote the bio-industry cluster, and international development. Pharmaceutical safety standards continue to improve gradually increased supervision, which will lead to reshuffle the entire industry to accelerate the policy, industry concentration is increased gradually. With the bio-pharmaceutical sector booming worldwide, more and more multinational pharmaceutical companies will look and energy into this area, and began to further explore the Chinese pharmaceutical market of great potential.



Biopharmaceutical research and development of new products requires a lot of money, new product development there is a big uncertainty, but a successful product often give investors huge profits. Biopharmaceutical companies to venture capital in the venture capital stage of mainly, as the business matures and begins to increase common equity capital to achieve economies of scale in production and sales, they began to absorb the debt funds such as corporate bonds and bank loans.



In recent years, the global epidemic of influenza A H1N1 influenza epidemic, brought in for the hot selling products such as vaccines, but also makes biomedical industry concern, the major venture capital institutions have close watch on the field. In 2009, venture capitalists frequently shot on the bio-pharmaceutical industry in the domestic investment in the biomedical field action continued. Series of venture capital investment reflects the favor of the industry body, eyes on the potential growth in this area.



For bio-pharmaceutical high input, high-risk, high technology, the characteristics of a long development time, save through the acquisition and development investment, reduce investment risk, the use of existing scientific and technical personnel and equipment, reducing the payback period, acquirers can use the acquired company market position, such as ready-made marketing network, and its relationship with local customers and suppliers over the years established credit, so that enterprises can immediately place in the local market.



In 2008 the international financial crisis, diversification of active pharmaceutical giant, have adopted to integrate the strength of the M & A, in response to the crisis but also for operation after the crisis has laid a solid foundation. In 2009, appeared in the global pharmaceutical industry had a magnificent wave of mergers. July 2009 the world's second largest pharmaceutical company GlaxoSmithKline (GSK) has been approved by the European Commission, with 36 billion acquisition of the world's largest independent pharmaceutical company Stiefel Laboratories American skin care company. The acquisition gives GSK the skin-care products business increased to three times the original, and the share of the global cosmeceutical market share of 8%.



November 4, 2009, Johnson & Johnson announced its global restructuring plan. Following the April 2009 price of 5 billion acquisition of biotechnology companies BiParSciences company, in July the acquisition of Indian companies Shantha vaccine after October 1, Sanofi - Aventis announced, will be 370 million euros (about 5.38 billion) acquisition of French development of ophthalmic products, biotechnology companies Fovea company. Sanofi - Aventis continues to look for hunting. Past 10 years, the world's largest drug manufacturer Pfizer has invested $ 222,200,000,000 was 8 times larger acquisitions, rapid growth for the world's largest pharmaceutical companies. Have been obtained in the European Union, China, the United States and Canada, after the adoption of conditional approval, Pfizer in cash and stock acquisition of Wyeth. Chemical drug boss Wyeth, Pfizer hopes to seize the bio-pharmaceutical M & A bridgehead.



Look forward to stronger medicine circulation



Pharmaceutical distribution industry is connected upstream and downstream retail pharmaceutical enterprises an important part of the terminal. Pharmaceutical distribution companies from the upstream procurement of medicines pharmaceutical enterprises, and then to the downstream of the pharmaceutical wholesale distribution companies, hospitals, pharmacies and so on, through the trading post and provide value-added services for profit. Pharmaceutical distribution companies in the pharmaceutical industry is the important part, plays a key role in connecting link.



Developed countries, pharmaceutical distribution market is more mature, focused and high wholesale segment, "scale, intensive" features more distinctly. Drug sales in the U.S. share of total world pharmaceutical market more than 40%, but were only 75 drug wholesalers, the top three market share up to 96%; the European Union's top three drug distribution business, its market share 65%; France eight pharmaceutical wholesale enterprises, the top three market share up to 95%; Germany retained only 10 major drug wholesalers, the top three market share of 60% to 70%; and like Denmark, Norway, Sweden and other small, only 2 to 3 national pharmaceutical wholesale enterprises, the concentration is high; Japanese pharmaceutical sales accounted for 12% of the world pharmaceutical market, the country only 147 drug distribution business, the first three Name of the market share of 74%. As the pharmaceutical market concentration is very high, these countries can not only be a very effective drug market regulation, and supervision costs are reduced. Pharmaceutical market in developed countries, the history of that area of ​​China's pharmaceutical business is still huge room to improve concentration, in the next period of time, pharmaceutical commercial enterprises is the competition pattern of concentration will be increased substantially.



From the global market, the United States, Japan and other countries have experienced a decade of major pharmaceutical merger integration, the pharmaceutical distribution market concentration greatly increased. Such as Japan in ten years time, the pharmaceutical distribution market concentration from 21% to 67%; while the United States within a decade, the pharmaceutical distribution market concentration is increased to 96%. From 2002 to 2008, China's pharmaceutical business sectors of the situation, China's pharmaceutical business sector concentration is steadily improving, are walking and the United States and Japan similar development path.



The next decade, China's pharmaceutical distribution market will enter a phase of rapid integration, market concentration will be significantly enhanced. China's pharmaceutical industry is currently in circulation in a relatively fragmented market situation, the end of 2008, China's pharmaceutical quality management specification has certified more than 13,000 pharmaceutical distribution companies.



In recent years, benefiting from industry consolidation, large pharmaceutical distribution company's market share has been on the rise, the market concentration is not in continuous improvement. According to China Association of Pharmaceutical Commerce statistics, in 2003 and 2008, China's three major pharmaceutical distribution companies - China National Pharmaceutical Group Corporation, Shanghai Pharmaceutical Co., Ltd. and Kyushu Pharmaceutical Group Inc. has combined market share of 12.7% to 20%; the top ten pharmaceutical distribution companies in the total market share from 26.1% to 34.6%, industry concentration has increased dramatically. Sales of more than 50 billion business number also from 6 to 11; more than 20 billion business number from 17 to 42, industry scale is gradually formed.



R & D outsourcing in the ascendant



Pharmaceutical outsourcing (contract research organization, CRO, ContractResearchOrganization) began in Europe, refers to a number of large pharmaceutical companies to outsource non-core R & D areas, to improve efficiency, save 30% to 50% of the cost.



Professional bodies which pharmaceutical R & D outsourcing came into being and gradually formed a substantial size of the market. In 2009, the world's leading pharmaceutical research and development outsourcing companies such as Quintiles, Covance, PPD, etc., their annual revenue over 10 billion U.S. dollars. China's CRO industry is relatively young, and if set up in 2000 as the industry WuXi the first year, the local CRO company currently has only a decade old. CRO business, driven by international and Chinese policy to encourage new drug R & D environment, the Chinese CRO industry has been developing rapidly. In just five or six years time, China has emerged in the CRO more than 100 enterprises engaged in the compounds of outsourcing, research outsourcing of bulk drugs, formulations outsourcing of preclinical studies and clinical research outsourcing, outsourcing of R & D segments . The data show that in 2008, pharmaceutical R & D outsourcing market in China has risen to about 2.6 billion U.S. dollars, compared with $ 25,000,000 in 2005 a full size of the market grew by more than 10 times in 2010, is expected to grow to 4.30 billion U.S. dollars. Reduce the traditional pharmaceutical industry is accelerating internal development efforts and increase the proportion of R & D outsourcing.



CRO in this young industry is very rapid development momentum in China, won the support of local government. Yizhuang such as Beijing, Shanghai Zhangjiang Hi-Tech Park has formed a CRO industry cluster. They are more "high value-added, high margin," the industry characteristics favor of attracting venture capital. If clinical trials of Qiming Venture Partners invested CRO Tiger; Warburg Pincus, General Atlantic, Fidelity Asia, investing in China, the world funds and has invested in Fidelity biological WuXi PharmaTech. In 2007, WuXi PharmaTech's successful listing on the NYSE light up the future of the industry.



Mergers of small bio-active pharmaceutical companies have become multinational pharmaceutical companies quick access to a huge market potential of new drugs a good way, CRO CRO has become a merger between the research and development to improve efficiency, expand their business and seek effective means to a larger market share. The end of October 2009, the global CRO PPD, the top three areas to enhance the layout in China, was established in 2000 acquired the provision of clinical services by Gus Beijing medical technology company. By Gus has 300 employees in China, and PPD in the global scale has 10,000 employees. In the same year in December, PPD company has invested 77 million U.S. dollars acquisition of one of north China's largest CRO BioDuro technology. The latter is mainly engaged in pre-clinical studies, clinical study for PPD to provide a good foundation. Once caused a huge sensation CharlesRiver the industry's largest CRO WuXi acquisition of merger activities in the final major shareholder of the acquirer and the suspension of the opposition, the former WuXi PharmaTech therefore paid to the $ 30,000,000 compensation for breach of contract.



The CRO in China local enterprises, vertical integration through acquisitions, to extend the industrial chain, expanding profit growth. January 2009, Hong Long get into Europe through the acquisition of GLP toxicology services to the international certification of Victory Bo (China), to the drug development business from the previous study on the expansion to be able to provide all pre-clinical chemistry services, will present its line of sight aimed at the more profitable aspects of the biological test, said it would expand the appropriate business and achieve profitable growth.
 
 
Of:
Source: China Pharmaceutical News
Posted by: Yiyun

• 上一篇文章： 中药产业:中国人手中的金矿